Victory Capital Management Inc. Makes New Investment in SI-BONE, Inc. (NASDAQ:SIBN)

Victory Capital Management Inc. acquired a new position in SI-BONE, Inc. (NASDAQ:SIBNFree Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 320,196 shares of the company’s stock, valued at approximately $6,721,000. Victory Capital Management Inc. owned 0.79% of SI-BONE as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. RiverPark Advisors LLC bought a new position in shares of SI-BONE in the 3rd quarter worth approximately $55,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of SI-BONE by 48.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,435 shares of the company’s stock worth $158,000 after acquiring an additional 2,437 shares in the last quarter. Arizona State Retirement System raised its position in shares of SI-BONE by 7.7% in the 4th quarter. Arizona State Retirement System now owns 10,675 shares of the company’s stock worth $224,000 after acquiring an additional 762 shares in the last quarter. Semanteon Capital Management LP bought a new position in shares of SI-BONE in the 4th quarter worth approximately $251,000. Finally, Bailard Inc. bought a new position in shares of SI-BONE in the 4th quarter worth approximately $269,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Analyst Upgrades and Downgrades

SIBN has been the subject of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $27.00 target price on shares of SI-BONE in a research report on Tuesday, May 7th. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 27th. Piper Sandler began coverage on SI-BONE in a research report on Thursday, March 28th. They issued an “overweight” rating and a $25.00 target price for the company. Truist Financial reaffirmed a “buy” rating and set a $24.00 price objective (down previously from $26.00) on shares of SI-BONE in a research report on Tuesday, February 27th. Finally, Morgan Stanley reduced their price objective on SI-BONE from $26.00 to $25.00 and set an “overweight” rating for the company in a research report on Tuesday, May 7th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $27.29.

Get Our Latest Report on SI-BONE

Insiders Place Their Bets

In other SI-BONE news, CFO Anshul Maheshwari sold 2,425 shares of SI-BONE stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total value of $37,466.25. Following the completion of the sale, the chief financial officer now owns 205,516 shares of the company’s stock, valued at approximately $3,175,222.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Anthony J. Recupero sold 3,307 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.50, for a total value of $51,258.50. Following the transaction, the insider now directly owns 252,453 shares in the company, valued at approximately $3,913,021.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Anshul Maheshwari sold 2,425 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $15.45, for a total value of $37,466.25. Following the completion of the transaction, the chief financial officer now owns 205,516 shares in the company, valued at $3,175,222.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,905 shares of company stock valued at $190,273. Corporate insiders own 5.40% of the company’s stock.

SI-BONE Stock Down 2.2 %

SIBN stock opened at $14.67 on Wednesday. The firm has a market cap of $604.48 million, a PE ratio of -13.46 and a beta of 1.24. The business has a 50 day moving average of $15.60 and a 200 day moving average of $17.94. SI-BONE, Inc. has a twelve month low of $13.96 and a twelve month high of $29.51. The company has a quick ratio of 8.75, a current ratio of 9.76 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBNGet Free Report) last posted its earnings results on Monday, February 26th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The business had revenue of $38.86 million during the quarter, compared to analyst estimates of $38.60 million. SI-BONE had a negative return on equity of 25.14% and a negative net margin of 29.93%. On average, research analysts forecast that SI-BONE, Inc. will post -0.95 EPS for the current fiscal year.

About SI-BONE

(Free Report)

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

Recommended Stories

Want to see what other hedge funds are holding SIBN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SI-BONE, Inc. (NASDAQ:SIBNFree Report).

Institutional Ownership by Quarter for SI-BONE (NASDAQ:SIBN)

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.